Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLoh, Zoe-
dc.contributor.authorMitchell, Paul L R-
dc.contributor.authorJohn, Thomas-
dc.contributor.authorArulananda, Surein-
dc.identifier.citationInternal Medicine Journal 2019; 49(12): 1541-1545-
dc.description.abstractFirst-line tyrosine kinase inhibitors are standard of care for non-small-cell lung cancers (NSCLC) harbouring an epidermal growth factor receptor mutation, anaplastic lymphoma kinase fusion or c-ros oncogene 1 rearrangement. Other targetable oncogenic drivers have been identified but testing for these is neither funded nor commonly performed in Australia. Using a case example, we discuss the importance of considering several other genomic aberrations in our population, such as rearrangements in the RET proto-oncogene, which occur in 1-2% of lung adenocarcinoma. New oncogenic drivers and corresponding targeted agents are constantly being discovered; these will continue to refine the treatment of non-small-cell lung cancer in the era of precision medicine.-
dc.subjectRET rearrangement-
dc.subjectgenomic profiling-
dc.subjectnon-small-cell lung cancer-
dc.subjecttyrosine kinase inhibitor-
dc.titleRET-rearranged non-small-cell lung cancer and therapeutic implications.-
dc.typeJournal Article-
dc.identifier.journaltitleInternal Medicine Journal-
dc.identifier.affiliationDepartment of Medical Oncology, Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationCancer Immuno-Biology Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationSchool of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australiaen
dc.type.austinJournal Article-
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.grantfulltextnone- Newton-John Cancer Wellness and Research Centre- Oncology- Newton-John Cancer Wellness and Research Centre- Newton-John Cancer Research Institute- Oncology- Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Feb 2, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.